UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

CNS neuroscience & therapeutics, 2023-09, Vol.29 (9), p.2705-2716

2023

Volltextzugriff (PDF)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

Scientific reports, 2022-11, Vol.12 (1), p.20601-20601, Article 20601

2022

Volltextzugriff (PDF)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

BMC cancer, 2023-08, Vol.23 (1), p.745-745, Article 745

2023

Volltextzugriff (PDF)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

PloS one, 2022-12, Vol.17 (12), p.e0278725-e0278725

2022

Volltextzugriff (PDF)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

Scientific reports, 2022-11, Vol.12 (1), p.19555-11, Article 19555

2022

Volltextzugriff (PDF)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Frontiers in immunology, 2023-05, Vol.14, p.1169735-1169735

2023

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Frontiers in oncology, 2021-12, Vol.11, p.790373-790373

2021

Volltextzugriff (PDF)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China

Frontiers in oncology, 2022-04, Vol.12, p.851522-851522

2022

Volltextzugriff (PDF)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Pharmaceuticals (Basel, Switzerland), 2024-08, Vol.17 (8), p.1028

2024

Volltextzugriff (PDF)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

PloS one, 2022-12, Vol.17 (12)

2022

Volltextzugriff (PDF)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

Frontiers in immunology, 2023-01, Vol.14, p.1092385-1092385

2023

Volltextzugriff (PDF)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Frontiers in pharmacology, 2022-09, Vol.13, p.990241-990241

2022

Volltextzugriff (PDF)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Frontiers in public health, 2022-10, Vol.10, p.996179

2022

Volltextzugriff (PDF)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database

Cancer medicine (Malden, MA), 2023-02, Vol.12 (3), p.3365-3375

2023

Volltextzugriff (PDF)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china

Frontiers in pharmacology, 2022-08, Vol.13, p.818579-818579

2022

Volltextzugriff (PDF)

Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system

Heliyon, 2024-05, Vol.10 (9), p.e30437-e30437, Article e30437

2024

Volltextzugriff (PDF)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system

Frontiers in pharmacology, 2024-07, Vol.15, p.1431579

2024

Volltextzugriff (PDF)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

Frontiers in pharmacology, 2022-09, Vol.13, p.920479-920479

2022

Volltextzugriff (PDF)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Frontiers in pharmacology, 2022-06, Vol.13, p.862508-862508

2022

Volltextzugriff (PDF)

A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan

Food & function, 2018-06, Vol.9 (6), p.3114-3125

2018

Volltextzugriff (PDF)

Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway

Journal of functional foods, 2015-05, Vol.15, p.151-159

2015

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Cancer management and research, 2021-01, Vol.13, p.8297-8306

2021

Volltextzugriff (PDF)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report

BMC nephrology, 2023-03, Vol.24 (1), p.51-51, Article 51

2023

Volltextzugriff (PDF)

A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system

Expert opinion on drug safety, 2022-04, Vol.21 (4), p.563-572

2022

Volltextzugriff (PDF)

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Drug safety, 2023-09, Vol.46 (9), p.881-895

2023

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(79)
Tagungsberichte
(1)

Sprache

Englisch
(77)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(39)
Humans
(18)
Physical Sciences
(16)
Pharmacology & Pharmacy
(14)
Pharmacovigilance
(14)
Chemistry
(11)
Data Mining
(11)
Faers
(9)
Science & Technology - Other Topics
(9)
Technology
(9)
Algorithms
(8)
Multidisciplinary Sciences
(8)
Adverse Events
(7)
Fda Approval
(7)
Female
(7)
Pharmacology
(7)
Adverse Drug Reaction Reporting Systems
(6)
Adverse Event
(6)
Cancer Therapies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china

Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan

Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report

A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Suchergebnisse filtern